Is Beryl Drugs Ltd debt-free?

Yes, Beryl Drugs Ltd is debt-free with a debt-to-equity ratio of 0.43.

Home

Beryl Drugs Ltd

Beryl Drugs Ltd Financials

Beryl Drugs Ltd Financial Statement

Beryl Drugs Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars	Jun 2025	Mar 2025	Dec 2024
Revenue	4.84	5.22	5.40
Operating Expense	4.28	4.72	4.81
Net Profit	0.02	0.15	0.05
Net Profit Margin	0.41	2.87	0.93
Earning Per Share	0.04	0.30	0.10
EBIDTA	0.65	0.40	0.55
Effective Tax Rate	27.27	-30	11.86

Particulars	Jun 2025
Revenue	4.84
Operating Expense	4.28
Net Profit	0.02
Net Profit Margin	0.41
Earning Per Share	0.04
EBIDTA	0.65
Effective Tax Rate	27.27

Beryl Drugs Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2025	Mar 2024	Mar 2023
Total Revenue Annual	21.15	26.73	26.89
Operating Expenses Annual	19.91	24.45	24.94
Operating Profit Annual	2.64	2.67	2.21
Interest Annual	0.53	0.46	0.42
Depreciation	1.25	1.20	0.81
Net Profit Annual	0.58	0.77	0.77
Tax Annual	0.29	0.24	0.22

Particulars	Mar 2025
Total Revenue Annual	21.15
Operating Expenses Annual	19.91
Operating Profit Annual	2.64
Interest Annual	0.53
Depreciation	1.25
Net Profit Annual	0.58
Tax Annual	0.29

Beryl Drugs Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2025	Mar 2024	Mar 2023
Cash Flow at the Beginning	0.13	0.28	0.27
Cash Flow from Operations	2.64	0.82	2.48
Cash Flow from Investing	-0.40	-1.08	-1.30
Cash Flow from Financing	-1.55	0.10	-1.17
Cash Flow at the End	0.81	0.12	0.28

Particulars	Mar 2025
Cash Flow at the Beginning	0.13
Cash Flow from Operations	2.64
Cash Flow from Investing	-0.40
Cash Flow from Financing	-1.55
Cash Flow at the End	0.81

Beryl Drugs Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2025	Mar 2024	Mar 2023
PBDIT Margin (%)	12.53	10.03	8.44
PBIT Margin (%)	6.62	5.54	5.43
PBT Margin (%)	-5.72	-6.24	-6.14
Net PROFIT Margin (%)	2.74	2.88	2.86
Return On Networth / Equity (%)	6.30	9.07	10.03
Return On Networth /Employed (%)	9.93	10.80	10.76
Return On Assets (%)	4.09	5.62	5.67
Total Debt / Equity (X)	0.50	0.57	0.64
Asset Turnover Ratio (%)	1.49	1.95	1.98

Particulars	Mar 2025
PBDIT Margin (%)	12.53
PBIT Margin (%)	6.62
PBT Margin (%)	-5.72
Net PROFIT Margin (%)	2.74
Return On Networth / Equity (%)	6.30
Return On Networth /Employed (%)	9.93
Return On Assets (%)	4.09
Total Debt / Equity (X)	0.50
Asset Turnover Ratio (%)	1.49

Beryl Drugs Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2025	Mar 2024	Mar 2023
Fixed Assets Annual	6.01	5.96	5.81
Total Current Assets Annual	9.04	10.12	10.32
Non Current Assets Annual	6.92	7.36	7.20
Total Shareholders Funds Annual	9.50	8.92	8.07
Total Assets Annual	15.96	17.49	17.51

Particulars	Mar 2025
Fixed Assets Annual	6.01
Total Current Assets Annual	9.04
Non Current Assets Annual	6.92
Total Shareholders Funds Annual	9.50
Total Assets Annual	15.96

Beryl Drugs Ltd Earning Calls

No Data Availabe

Dividend Pages

PE Ratio

FAQS on Beryl Drugs Ltd Financials

As of Sep 29, 2025, Beryl Drugs Ltd has a market capitalization of 10.68 Cr. Value Research classifies it as a Micro-Cap company.

Yes, Beryl Drugs Ltd is with a debt-to-equity ratio of 0.43.

In FY 2024 , Beryl Drugs Ltd recorded a total revenue of approximately 21.15 Cr marking a significant milestone in the company's financial performance.

Beryl Drugs Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.3% and -0.1% annually, respectively..

Beryl Drugs Ltd's current PE ratio is 18.41.

Beryl Drugs Ltd's ROCE averaged 10.6% from the FY ending March 2023 to 2025, with a median of 10.5%. It peaked at 11.1% in March 2023, reflecting strong capital efficiency over the period..

Beryl Drugs Ltd's latest EBIT is Rs. 1.40 Cr, surpassing the average EBIT of Rs. 1.42 Cr over the 5 years..